• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨肉瘤局部复发的预测因素:540例肢体肿瘤患者在新辅助化疗后至少随访2.5年。

Predictive factors for local recurrence in osteosarcoma: 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy.

作者信息

Bacci G, Ferrari S, Mercuri M, Bertoni F, Picci P, Manfrini M, Gasbarrini A, Forni C, Cesari M, Campanacci M

机构信息

Section of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy.

出版信息

Acta Orthop Scand. 1998 Jun;69(3):230-6. doi: 10.3109/17453679809000921.

DOI:10.3109/17453679809000921
PMID:9703394
Abstract

We investigated predictive factors for local recurrence in 540 patients with non-metastatic osteosarcoma of the extremity treated with surgery and neoadjuvant chemotherapy, between March 1983 and October 1994. The median follow-up was 7.5 (2.5-15) years. Local recurrences developed in 31 (6%) patients after a median time of 2 (0.5-7) years. Local recurrence did not correlate with patients' age and sex, histologic subtype, site and tumor volume, presence of pathologic fracture, chemotherapy regimen and type of surgery. Local recurrence-free survival (LRFS) correlated with the quality of surgical margins and response to chemotherapy: the 7-year LRFS was 97% after adequate surgical margins and 71% after inadequate surgical margins (p < 0.0001), and was 95% in good responders and 90% in poor responders (p = 0.001). Only 1 of 31 patients with local recurrence was free of disease 15 months after the last treatment, 3 were alive with uncontrolled disease and 27 died. This post-relapse outcome is significantly worse than in patients who relapsed with metastases only (25% free of disease, 0.5-9 years after the last treatment). We conclude that, in osteosarcoma of the extremity, limb-salvage procedures should be planned only when the preoperative staging indicates that it is possible to achieve adequate surgical margins. If the pathologic examination of the surgical specimen shows inadequate surgical margins, an immediate amputation should be considered, especially if the histologic response to preoperative chemotherapy was poor.

摘要

我们调查了1983年3月至1994年10月间接受手术和新辅助化疗的540例肢体非转移性骨肉瘤患者局部复发的预测因素。中位随访时间为7.5(2.5 - 15)年。31例(6%)患者出现局部复发,中位时间为2(0.5 - 7)年。局部复发与患者的年龄、性别、组织学亚型、部位和肿瘤体积、病理性骨折的存在、化疗方案及手术类型均无相关性。局部无复发生存期(LRFS)与手术切缘质量及化疗反应相关:手术切缘充分后的7年LRFS为97%,切缘不充分后的为71%(p < 0.0001),化疗反应良好者为95%,反应不佳者为90%(p = 0.001)。31例局部复发患者中,仅1例在最后一次治疗后15个月无疾病,3例带瘤生存,27例死亡。这种复发后的结局明显差于仅出现转移复发的患者(25%无疾病,最后一次治疗后0.5 - 9年)。我们得出结论,在肢体骨肉瘤中,仅当术前分期表明有可能获得充分手术切缘时才应计划保肢手术。如果手术标本的病理检查显示手术切缘不充分,应考虑立即截肢,尤其是术前化疗的组织学反应不佳时。

相似文献

1
Predictive factors for local recurrence in osteosarcoma: 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy.骨肉瘤局部复发的预测因素:540例肢体肿瘤患者在新辅助化疗后至少随访2.5年。
Acta Orthop Scand. 1998 Jun;69(3):230-6. doi: 10.3109/17453679809000921.
2
Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.新辅助化疗治疗肢体骨肉瘤的预后因素:单机构789例患者的15年经验
Cancer. 2006 Mar 1;106(5):1154-61. doi: 10.1002/cncr.21724.
3
[Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients].[肢体局限性骨肉瘤的新辅助治疗。来自骨肉瘤协作研究组COSS的925例患者的结果]
Klin Padiatr. 1999 Jul-Aug;211(4):260-70. doi: 10.1055/s-2008-1043798.
4
Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution.肢体非转移性骨肉瘤的局部复发与局部控制:单机构27年经验
J Surg Oncol. 2007 Aug 1;96(2):118-23. doi: 10.1002/jso.20628.
5
Local and systemic control for osteosarcoma of the extremity treated with neoadjuvant chemotherapy and limb salvage surgery: the Rizzoli experience.新辅助化疗联合保肢手术治疗肢体骨肉瘤的局部和全身控制:里佐利经验
Oncol Rep. 2000 Sep-Oct;7(5):1129-33. doi: 10.3892/or.7.5.1129.
6
Influence of local recurrence on survival in patients with extremity osteosarcoma treated with neoadjuvant chemotherapy: the experience of a single institution with 44 patients.局部复发对接受新辅助化疗的肢体骨肉瘤患者生存的影响:一家机构对44例患者的经验。
Cancer. 2006 Jun 15;106(12):2701-6. doi: 10.1002/cncr.21937.
7
Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy.
Eur J Cancer. 2001 Jan;37(1):32-8. doi: 10.1016/s0959-8049(00)00361-0.
8
A Novel System for the Surgical Staging of Primary High-grade Osteosarcoma: The Birmingham Classification.一种用于原发性高级别骨肉瘤手术分期的新系统:伯明翰分类法。
Clin Orthop Relat Res. 2017 Mar;475(3):842-850. doi: 10.1007/s11999-016-4851-y.
9
Does amputation offer any survival benefit over limb salvage in osteosarcoma patients with poor chemonecrosis and close margins?对于化疗坏死效果不佳且切缘阳性的骨肉瘤患者,截肢相对于保肢是否具有任何生存益处?
Bone Joint J. 2015 Jan;97-B(1):115-20. doi: 10.1302/0301-620X.97B1.33924.
10
Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin.肢体骨肉瘤的初始化疗与延迟手术(新辅助化疗)。里佐利研究所对127例术前接受静脉注射甲氨蝶呤(高剂量与中等剂量)和动脉内顺铂治疗患者的经验。
Cancer. 1990 Jun 1;65(11):2539-53. doi: 10.1002/1097-0142(19900601)65:11<2539::aid-cncr2820651125>3.0.co;2-m.

引用本文的文献

1
Transcriptional profiling of canine osteosarcoma identifies prognostic gene expression signatures with translational value for humans.犬骨肉瘤的转录组分析确定了具有人类转化价值的预后基因表达特征。
Commun Biol. 2023 Aug 17;6(1):856. doi: 10.1038/s42003-023-05208-z.
2
The development of a novel signature based on the mA RNA methylation regulator-related ceRNA network to predict prognosis and therapy response in sarcomas.基于mA RNA甲基化调节因子相关ceRNA网络开发一种新型特征以预测肉瘤的预后和治疗反应。
Front Genet. 2022 Oct 12;13:894080. doi: 10.3389/fgene.2022.894080. eCollection 2022.
3
Evaluation of tumor-prostheses over time: Complications, functional outcome, and comparative statistical analysis after resection and reconstruction in orthopedic oncologic conditions in the lower extremities.
随着时间推移对肿瘤假体的评估:下肢骨肿瘤切除与重建后的并发症、功能结果及比较性统计分析
SAGE Open Med. 2022 Apr 21;10:20503121221094190. doi: 10.1177/20503121221094190. eCollection 2022.
4
A Nomogram for Predicting Cancer-Specific Survival of Osteosarcoma and Ewing's Sarcoma in Children: A SEER Database Analysis.基于 SEER 数据库的儿童骨肉瘤和尤文肉瘤特异性生存预测列线图分析
Front Public Health. 2022 Feb 1;10:837506. doi: 10.3389/fpubh.2022.837506. eCollection 2022.
5
Novel Scoring Criteria for Preoperative Prediction of Neoadjuvant Chemotherapy Response in Osteosarcoma.新型骨肉瘤新辅助化疗反应术前预测评分标准。
Iowa Orthop J. 2021 Dec;41(2):19-26.
6
The tumor immune microenvironment and immune-related signature predict the chemotherapy response in patients with osteosarcoma.肿瘤免疫微环境和免疫相关特征可预测骨肉瘤患者的化疗反应。
BMC Cancer. 2021 May 21;21(1):581. doi: 10.1186/s12885-021-08328-z.
7
Pretreatment Prediction of Relapse Risk in Patients with Osteosarcoma Using Radiomics Nomogram Based on CT: A Retrospective Multicenter Study.基于 CT 影像组学列线图预测骨肉瘤患者复发风险的预处理研究:一项回顾性多中心研究。
Biomed Res Int. 2021 Feb 4;2021:6674471. doi: 10.1155/2021/6674471. eCollection 2021.
8
Standard Treatment Remains the Recommended Approach for Patients with Bone Sarcoma Who Underwent Unplanned Surgery: Report from the Japanese Musculoskeletal Oncology Group.标准治疗仍是骨肉瘤患者接受非计划手术后的推荐治疗方法:来自日本肌肉骨骼肿瘤学组的报告。
Cancer Manag Res. 2020 Oct 12;12:10017-10022. doi: 10.2147/CMAR.S270178. eCollection 2020.
9
Combination Therapy with Disulfiram, Copper, and Doxorubicin for Osteosarcoma: Support for a Novel Drug Repurposing Strategy.双硫仑、铜和阿霉素联合治疗骨肉瘤:对一种新型药物重新利用策略的支持
Sarcoma. 2019 Jul 11;2019:1320201. doi: 10.1155/2019/1320201. eCollection 2019.
10
Clinical outcome of various limb salvage surgeries in osteosarcoma around knee: Megaprosthesis, extracorporeal irradiation and resection arthrodesis.膝关节周围骨肉瘤不同保肢手术的临床结果:人工关节置换、体外照射和切除关节融合术。
Ann Med Surg (Lond). 2019 Apr 24;42:14-18. doi: 10.1016/j.amsu.2019.04.005. eCollection 2019 Jun.